Risk-reducing endocrine therapy: lowering breast cancer risk

Risk-reducing endocrine therapy uses hormone-blocking medicine to lower the chance of certain breast cancers developing.

It is preventive treatment rather than treatment for an existing breast cancer. Medicines such as Tamoxifen affect oestrogen signalling, which is relevant because some breast cancers use oestrogen to grow.

A clinician reviews your personal and family history, breast findings, menstrual or menopause status, medicines and health conditions. The discussion compares the potential preventive benefit with side effects that matter for you.

If you choose treatment, tablets are taken regularly as prescribed, with planned reviews to check symptoms, adherence and any changes in health. Do not stop or restart the medicine without discussing it with the prescribing team.

Possible effects include hot flushes, sweats, changes in vaginal discharge or dryness, changes in periods, fatigue, nausea, headaches and mood changes. The pattern differs between medicines and between individuals.

Get prompt medical advice for leg swelling or pain, sudden chest pain, shortness of breath, unusual vaginal bleeding, jaundice, or a severe new headache with visual change. These symptoms need assessment, whether or not they are caused by the medicine.

These medicines can lower the likelihood of hormone-sensitive breast cancers developing in people selected because their risk is higher than average. They do not remove all possibility of breast cancer, and they are not the right option for every increased-risk situation.

Your clinician will explain the decision using the features that shape your own risk, including relevant family history, genetic information and breast tissue findings. Screening and attention to new breast changes remain part of care.

The medicine choice is tailored to menopausal status, past medical history and other medicines. Some medicines can interact with endocrine therapy, so share prescriptions, non-prescription products and supplements at every review.

This approach may be discussed with people whose breast cancer risk is increased because of family history, a BRCA Gene Mutation, or certain breast tissue findings such as Lobular Carcinoma In Situ. A specialist assessment clarifies whether endocrine prevention fits your situation.

The first visit establishes your reasons for considering prevention and checks for factors that could alter the choice. You will receive directions for taking the medicine and information about symptoms that should trigger a call.

At follow-up, the clinician asks about side effects, checks relevant health concerns, and revisits the balance between continuing treatment and your quality of life. Tell the team if you are planning pregnancy, become pregnant or are breastfeeding.

There is no surgical recovery period, but the body may need time to adjust to hormonal effects. Keep follow-up appointments, note persistent symptoms, and use the contact route provided by your clinic rather than making medication changes on your own.

The risk profile differs by medicine and your health history. Blood clots, uterine changes, liver problems and bone-health considerations may be relevant for some endocrine treatments. Previous clots, unexplained bleeding and planned surgery should be discussed before treatment begins.

Alternatives can include tailored screening, lifestyle support, genetic counselling, or risk-reducing surgery for selected people. The best approach may combine more than one measure, based on the type of increased risk and what feels acceptable to you.

A breast specialist, medical oncologist, gynaecologist or genetics service may contribute to the decision. Ask who will monitor side effects, how to contact the team between appointments, and how preventive treatment fits with your screening plan.